AUS
NZ
UK
CA
USA
IND
Healthcare
Lumos Diagnostics Adds Tenmile Ventures as New Shareholder
September 04, 2024 05:19 PM AEST| By Team Kalkine MediaLumos Diagnostics Holdings Ltd,(ASX:LDX),is raising A$10 million through a pro rata accelerated non-renounceable entitlement offer, with the retail component underwritten up to approximately A$6 million. The offer has generated significant interest,...
The Transformative Impact of Regenerative Medicine on Healthcare
September 04, 2024 05:15 PM AEST| By Team Kalkine MediaRegenerative medicine is revolutionizing health care by focusing on repairing, replacing, or regenerating damaged or diseased cells, tissues, or organs to restore normal function. This emerging field integrates biology, engineering, and clinical prac...
Lumos Diagnostics Gains Twiggy Forrest as Key Investor in $10M Raise
September 04, 2024 05:12 PM AEST| By Team Kalkine MediaEmerging companies Lumos Diagnostics, Memphasys, and Vitura Health are making notable strides in their respective sectors. From advancing diagnostic technologies to revolutionizing fertility solutions and expanding telehealth services, these,ASX heal...
Lumos Diagnostics Wins Twiggy Forrest as Major Investor
September 04, 2024 12:56 PM AEST| By Team Kalkine MediaIn today's market updates, Lumos Diagnostics aims to raise $10 million to advance its diagnostic technology, while,ASX healthcare stock,Memphasys ventures into the equine fertility sector with its innovative sperm-selection device. Vitura Health also...
Noxopharm Targets Challenging Brain Cancer with New Developments
September 03, 2024 04:17 PM AEST| By Team Kalkine MediaThis week, several,ASX-listed healthcare stocks,made headlines with notable updates. Noxopharm Ltd achieved promising results in glioblastoma treatment, Percheron Therapeutics Ltd reported encouraging data for epilepsy, and Cyclopharm Ltd recorded it...
CSL Ltd: A Closer Look at the Biotechnology Leader
September 02, 2024 04:35 PM AEST| By Team Kalkine MediaSince the start of 2024, CSL Ltd,(ASX: CSL),has seen its share price rise by 6.0%. This growth has sparked significant interest among investors. Here’s a detailed look at why CSL shares are attracting attention and what makes this biotechnology compa...
Emyria (ASX:EMD) Sees 10% Surge on Promising Interim Results for MDMA-Assisted Therapy in PTSD Treatment
September 02, 2024 11:05 AM AEST| By Team Kalkine MediaOn Monday, shares of Emyria (ASX:EMD) experienced a notable 9.4% increase, reaching 3.5 cents per share, following the announcement of positive interim results from their MDMA-assisted psychotherapy trials for PTSD patients.,The interim data revealed...
Private Hospitals Face Increasing Challenges Amid Financial and Operational Pressures
September 02, 2024 09:58 AM AEST| By Team Kalkine MediaRecent findings by the Health Department have raised concerns over the viability of private hospitals in Australia, highlighting a potential crisis within the,healthcare sector.,The review, led by Health Department Secretary Blair Comley, points to a...
Ramsay Health Falls Short of Investor Expectations as Rising Costs Impact Margins
August 30, 2024 02:16 PM AEST| By Team Kalkine MediaRamsay Health Care Ltd,(ASX: RHC),, Australia’s largest private hospital operator, has revealed significant challenges in its latest financial update. The company is set to demand increased funding from insurers if wage growth surpasses expectations,...
Oneview Healthcare Records Loss in Recent Financial Year. What are Future Plans?
August 29, 2024 05:28 PM AEST| By Team Kalkine MediaOneview Healthcare PLC (ASX:ONE) is a healthcare technology company that develops and sells software and consultancy services to the healthcare sector across various regions, including Ireland, the United States, Australia, Asia, and the Middle East....
Telix Submits Pixclara to FDA for Review
August 28, 2024 06:02 PM AEST| By Team Kalkine MediaTelix Pharmaceuticals,(ASX: TLX),has made significant progress in its efforts to enhance brain cancer diagnostics. The company recently filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for TLX101-CDx (Pixclara), an in...
Pacific Smiles Sees Strong Start to FY2025 with 10.9% Increase in Patient Fees
August 28, 2024 10:05 AM AEST| By Team Kalkine MediaPacific Smiles Group (ASX: PSQ) has reported a promising start to the 2024-25 financial year, with patient fees rising by 10.9% to $50.8 million in the first two months. This positive momentum reflects the company’s efforts to enhance the utilization...
Nanosonics (ASX:NAN) Shares Surge 11.85% on FY24 Results
August 27, 2024 05:17 PM AEST| By Team Kalkine MediaNanosonics Ltd (ASX:NAN) saw a significant boost in its share price on Tuesday, rising 11.85% to AU$3.02 following the release of its full-year FY24 results. The stock, which opened at AU$2.86, climbed to an intraday high of AU$3.08 as investors reac...
Actinogen Medical's (ASX:ACW) sharer price jumps 463% in 5 years, drops 47% in a month
August 27, 2024 05:01 PM AEST| By Team Kalkine MediaActinogen Medical Limited (ASX:ACW) has seen a sharp 47% decline in its share price over the past month, leaving shareholders concerned about the short-term outlook. However, when viewed over a more extended period, the company’s performance remains...
Tryptamine Therapeutics (ASX:TTM) Completes First-Ever IV Psilocin Injections to Set Safety Baseline
August 26, 2024 12:17 PM AEST| By Team Kalkine MediaHeadlines:,Completion of Initial Study:,Tryptamine Therapeutics (ASX:TYP) has finalized its first intravenous (IV) psilocin injection study with 11 patients, focusing on establishing baseline safety data.,Safety and Dosage Focus:,The study, involving...
Actinogen's Xanamem Shows Notable Advances with Four-Week 10mg Daily Regimen
August 26, 2024 11:27 AM AEST| By Team Kalkine MediaHeadlines,Promising Results for Xanamem:,Actinogen’s novel antidepressant, Xanamem, has shown significant efficacy in treating major depression with a daily 10mg dose, leading to a 30% increase in the company's share price.,Unique Mechanism of Action...
Fisher & Paykel (ASX: FPH) Updates Profit Forecast for FY25
August 23, 2024 10:34 AM AEST| By Team Kalkine MediaFisher & Paykel Healthcare Corporation Ltd (ASX: FPH) has revised its profit forecast for the fiscal year 2025, anticipating a net profit after tax (NPAT) of between $320 million and $370 million. This forecast represents an increase from the previou...
Clarity Pharmaceuticals and Next Science: Key Updates in the Biotech Sector
August 22, 2024 06:25 PM AEST| By Team Kalkine MediaClarity Pharmaceuticals,(ASX: CU6),has received a significant boost with the FDA granting 'Fast Track' designation to its new imaging agent, 64Cu-SAR-bisPSMA, designed for detecting prostate cancer. This designation is set to accelerate the developme...
US FDA Grants Fast Track Status to Clarity Pharma’s (ASX:CU6) Innovative Prostate Cancer PET Imaging Compound
August 22, 2024 11:57 AM AEST| By Team Kalkine MediaHighlights:,FDA Fast Track Status,:,Clarity Pharmaceuticals has received fast track status from the US FDA for its prostate cancer imaging compound, 64Cu-SAR-bisPSMA, which is designed for PET scans.,Accelerated Approval,:,The,fast track,designation...
Osteopore (ASX:OSX) Completes 3D-Printed Bone Implant Study Funded by Chilean Government
August 22, 2024 10:30 AM AEST| By Team Kalkine MediaOsteopore Limited (ASX:OSX),has successfully concluded a research program funded by the Chilean government, focused on developing a 3D-printed bone implant designed to enhance regenerative healing. This research marks a significant milestone for the...
Advertise your brand on Kalkine Media